ERBB2 and sarcoma: This specific case is supported by e.g., public datasets (Barretina et al, 2012; McDonald et al, 2017) for nine of the sarcoma lines used here, for which no oncogenic driver alteration has been found for EGFR or HER2 (Dataset EV1).